EMA Requests Suspending Sales of Hundreds of Drugs Due to Flawed Data from Indian CRO

The EMA is recommending that the European Commission suspend the sales of more than 300 generic drug formulations that were approved from flawed bioequivalence studies conducted at two of Micro Therapeutic Research Labs’ facilities in India.
Source: Drug Industry Daily